Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.addr.2021.01.014 http://scihub22266oqcxt.onion/10.1016/j.addr.2021.01.014 33482248!7816567!33482248     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Drug+Deliv+Rev 2021 ; 172 (ä): 314-338 Nephropedia Template TP {{tp|p=33482248|t=2021. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?|pdf=|usr=}}{{33482248}} gab.com Text SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand JO: Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=33482248 #FOAvip The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses. Twit Text FOAVip SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand ????Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=33482248 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33482248 #FOAvip English Wikipedia <ref>{{Cite pmid|33482248}}</ref> SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? #MMPMID33482248 Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT Adv Drug Deliv Rev 2021[May]; 172 (ä): 314-338 PMID33482248show ga The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses. |Animals[MESH] |COVID-19 Vaccines/*administration & dosage/chemistry/immunology[MESH] |COVID-19/epidemiology/immunology/*prevention & control[MESH] |Clinical Trials, Phase III as Topic/*methods[MESH] |Drug Evaluation, Preclinical/methods/trends[MESH] |Humans[MESH] |Protein Structure, Secondary[MESH] |Protein Structure, Tertiary[MESH]SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?(epmc).pdf DeepDyve Pubget Overpricing